Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur VERONIQUE VESPERINI

📍 Montpellier (34)HospitalierRPPS 10100177921
📊 Reconnaissance scientifique : 4/100📝 5 articles publiés📚 HAL (2)🏆 2 DU/DIU

✨ Profil synthétique

IA · 06/05/2026

Le Docteur Véronique Vesperini est une rhumatologue hospitalière à Montpellier, titulaire de plusieurs diplômes universitaires validés, notamment en médecine manuelle et en évaluation et prise en charge de la douleur. Ses recherches portent principalement sur les maladies rhumatismales et les troubles du squelette. Avec un h-index de 4 et 5 publications, elle contribue à l'avancement des connaissances dans son domaine.

Expertises présumées

  • Rhumatoides
  • Sclérodermie systémique
  • Chirurgie du pied et de la cheville
  • Scoliose
  • Pathologies tendineuses
  • Médecine manuelle
  • Évaluation et prise en charge de la douleur

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🏅 DU / DIU

  • DIU Médecine manuelle et Ostéopathie
  • DIU Etudes approfondies polyarthrites-maladies

🎓 Diplômes

  • Diplôme de Podologie
  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

4

h articles cités ≥ h fois chacun. Un h de 4 = 4 publications avec 4+ citations.

Citations

74

Publications

5

i10-index

3

Thématiques principales

  • Rheumatoid Arthritis Research and Therapies ×2
  • Systemic Sclerosis and Related Diseases ×2
  • Foot and Ankle Surgery ×1
  • Scoliosis diagnosis and treatment ×1
  • Tendon Structure and Treatment ×1

Affiliations FR : Laboratoire de Biotechnologie de l'Environnement

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort

    Arthritis care & research · 2013

    📚 34 citations🎯 RCR 1.37
    Lire l'abstract Crossref ↓

    ObjectiveTo investigate the initial response to treatment and risk of radiographic disease progression in current smokers (S), ex‐smokers (EX), and nonsmokers (NS) in a prospective early arthritis cohort and to analyze the influence of smoking cessation on arthritis outcome.MethodsThe ESPOIR cohort is a prospective cohort study monitoring clinical, biologic, and radiographic data for patients with inflammatory arthritis lasting 6 weeks to 6 months. We examined the influence of smoking status on disease presentation (baseline characteristics) and therapeutic response at 1 year. Risk of structural progression at 12 months, defined as change in the modified Sharp/van der Heijde score ≥1, was analyzed by multivariate regression adjusted for potential confounders (age, sex, joint erosion at inclusion, educational level, positivity for rheumatoid factor or anti–cyclic citrullinated peptide 2 antibodies, and shared HLA–DRB1 epitope).ResultsA total of 813 patients were included; 641 (79%) fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for rheumatoid arthritis (RA). At inclusion, 138 (21.5%) were S patients, 168 (26.2%) were EX patients, and 335 (52.3%) were NS patients. Baseline acute‐phase indicator values were significantly lower for S patients than EX and NS patients (mean ± SD erythrocyte sedimentation rate was 24.2 ± 18.2 mm/hour versus 33.4 ± 28.0 and 31.4 ± 25.0 [P = 0.02], respectively, and mean ± SD C‐reactive protein level was 17.7 ± 28.0 mg/dl versus 28.5 ± 42.5 and 21.4 ± 29.0 [P = 0.01], respectively). Smoking status had no influence on Disease Activity Score in 28 joints, Health Assessment Questionnaire score, EULAR response, or use of disease‐modifying antirheumatic drugs and biologic therapy in the first 12 months of followup (P > 0.05). The adjusted risk for structural disease progression was associated with active smokers (odds ratio 0.50 [95% confidence interval 0.27–0.93], P = 0.028). Sixteen patients had stopped smoking at 12 months, with no significant difference in observed outcomes from other patients.ConclusionIn this large prospective cohort of patients with early arthritis, smoking status had no significant effect on disease activity and disability but did reduce 1‐year radiographic disease progression. The antiinflammatory role of nicotine may explain the lower systemic inflammation and structural disease progression in current smokers with early RA.

  • 2
    In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study

    RMD open · 2023

    📚 9 citations🎯 RCR 1.63🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Background Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM). Objectives To assess the significance of DH/BS in patients with IM. Methods Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1. Results 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p<0.0001) and the diagnosis of IM was delayed (6 months vs 3 months, p=0.009). Weakness prevailing in the upper limbs (42.9% vs 15.3%), dysphagia (57.1% vs 25.5%), muscle atrophy (65.3% vs 34.7%), weight loss (61.2% vs 23.5%) and loss of the ability to walk (24.5% vs 5.1%) were hallmarks of DH/BS-IM (p≤0.0005), for which the patients more frequently received intravenous immunoglobulins (65.3% vs 34.7%, p=0.0004). Moreover, DH/BS-IM patients frequently featured signs and/or complications of systemic sclerosis (SSc), fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for this disease in 40.8% of the cases (vs 5.1%, p<0.0001). Distribution of the myopathy, its severity and its association with SSc were independently associated with DH/BS (p<0.05). Mortality was higher in the DH/BS-IM patients and loss of walking ability was independently associated with survival (p<0.05). Conclusion In IM patients, DH/BS is a marker of severity and is associated with SSc (scleromyositis).

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal3

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.